STAT1 expression and activation is increased in lesional psoriatic skin

British Journal of Dermatology

Volumn 168, Issue 2, 2013, Pages 302-310

  Hald, A ^a   Andres R M ^b   Salskov Iversen, M L ^a   Kjellerup, R B ^a   Iversen, L ^a   Johansen, Claus ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALPHA INTERFERON; GAMMA INTERFERON; LUCIFERASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE C DELTA; ROTTLERIN; STAT1 PROTEIN;

ARTICLE; CELL ASSAY; CELL CULTURE; CELL LYSATE; CONTROLLED STUDY; GENE EXPRESSION; GENE INDUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOPATHOGENESIS; KERATINOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PSORIASIS; REPORTER GENE; RNA ISOLATION; SKIN BIOPSY; ULTRAVIOLET B RADIATION; WESTERN BLOTTING;

CELLS, CULTURED; FIBROBLASTS; HUMANS; INTERFERONS; INTERLEUKIN-6; KERATINOCYTES; MAP KINASE SIGNALING SYSTEM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PSORIASIS; RNA, MESSENGER; SKIN; STAT1 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION; ULTRAVIOLET RAYS;

EID: 84873188114     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12049     Document Type: Article

References (29)

1. Stern RS,. Psoriasis. Lancet 1997; 350: 349-53.
2. Koo J,. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14: 485-96.
3. Christophers E,. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-20.
4. Johansen C, Funding AT, Otkjaer K, et al. Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol 2006; 176: 1431-8.
5. Johansen C, Moeller K, Kragballe K, et al. The activity of caspase-1 is increased in lesional psoriatic epidermis. J Invest Dermatol 2007; 127: 2857-64.
6. McKenzie RC, Sabin E,. Aberrant signalling and transcription factor activation as an explanation for the defective growth control and differentiation of keratinocytes in psoriasis: a hypothesis. Exp Dermatol 2003; 12: 337-45.
7. Van der Fits L, Van der Wel LI, Laman JD, et al. In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J Invest Dermatol 2004; 122: 51-60.
8. Eriksen KW, Lovato P, Skov L, et al. Increased sensitivity to interferon-alpha in psoriatic T cells. J Invest Dermatol 2005; 125: 936-44.
9. Racz E, Prens EP, Kurek D, et al. Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J Invest Dermatol 2011; 131: 1547-58.
10. Fridman JS, Scherle PA, Collins R, et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol 2011; 131: 1838-44.
11. Chang BY, Zhao F, He X, et al. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol 2009; 183: 2183-92.
12. Darnell JE Jr,. STATs and gene regulation. Science 1997; 277: 1630-5.
13. Sakatsume M, Igarashi K, Winestock KD, et al. The Jak kinases differentially associate with the alpha and beta (accessory factor) chains of the interferon gamma receptor to form a functional receptor unit capable of activating STAT transcription factors. J Biol Chem 1995; 270: 17528-34.
14. Igarashi K, Garotta G, Ozmen L, et al. Interferon-gamma induces tyrosine phosphorylation of interferon-gamma receptor and regulated association of protein tyrosine kinases, Jak1 and Jak2, with its receptor. J Biol Chem 1994; 269: 14333-6.
15. Darnell JE Jr, Kerr IM, Stark GR,. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-21.
16. Goh KC, Haque SJ, Williams BR,. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J 1999; 18: 5601-8.
17. Decker T, Kovarik P,. Serine phosphorylation of STATs. Oncogene 2000; 19: 2628-37.
18. Uddin S, Sassano A, Deb DK, et al. Protein kinase C-delta (PKC-delta) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem 2002; 277: 14408-16.
19. Johansen C, Vinter H, Soegaard-Madsen L, et al. Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFalpha therapy. Br J Dermatol 2010; 163: 1194-204.
20. Zhong Z, Wen Z, Darnell JE Jr,. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994; 264: 95-8.
21. Kordula T, Bugno M, Goldstein J, et al. Activation of signal transducer and activator of transcription-3 (Stat3) expression by interferon-gamma and interleukin-6 in hepatoma cells. Biochem Biophys Res Commun 1995; 216: 999-1005.
22. Schindler C, Levy DE, Decker T,. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007; 282: 20059-63.
23. Yao Y, Richman L, Morehouse C, et al. Type I interferon: potential therapeutic target for psoriasis? PLoS ONE 2008; 3: e2737.
24. Shoenfelt JL, Fenton MJ,. TLR2- and TLR4-dependent activation of STAT1 serine phosphorylation in murine macrophages is protein kinase C-delta-independent. J Endotoxin Res 2006; 12: 231-40.
25. Johansen C, Kragballe K, Westergaard M, et al. The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol 2005; 152: 37-42.
26. Rahman A, Anwar KN, Uddin S, et al. Protein kinase C-delta regulates thrombin-induced ICAM-1 gene expression in endothelial cells via activation of p38 mitogen-activated protein kinase. Mol Cell Biol 2001; 21: 5554-65.
27. West K,. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Investig Drugs 2009; 10: 491-504.
28. Mesa RA,. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs 2010; 13: 394-403.
29. Stump KL, Lu LD, Dobrzanski P, et al. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res Ther 2011; 13: R68.